Patents Assigned to Cell Design Labs, Inc.
  • Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
    Patent number: 12065498
    Abstract: Provided herein are chimeric antigen receptors that binds specifically to B-cell maturation antigen (BCMA) and CD307e, nucleic acids that encode these chimeric antigen receptors, and methods of making and using these chimeric antigen receptors.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 20, 2024
    Assignee: Cell Design Labs, Inc.
    Inventors: Peter Emtage, Stephen Santoro, Stephanie Secrest
  • Chimeric polypeptides and methods of altering the membrane localization of the same
    Patent number: 11993660
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: May 28, 2024
    Assignee: CELL DESIGN LABS, INC.
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • Methods and compositions for reducing the immunogenicity of chimeric notch receptors
    Patent number: 11325957
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Cell Design Labs, Inc.
    Inventors: Amy Gilbert, Vladimir Slepushkin, Peter Emtage, Anselm Levskaya, Spencer Scott
  • Chimeric polypeptides and methods of altering the membrane localization of the same
    Patent number: 11111310
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 7, 2021
    Assignee: Cell Design Labs, Inc.
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage